About: http://data.cimple.eu/news-article/a30da19e2416e939e8761ea35e3f2d1fd8bc262320196717962cd733     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The US Food and Drug Administration made public its guidance for issuing emergency approval for a Covid-19 vaccine on Tuesday, making it clear it wants to see follow-up two months after trial volunteers have their second dose. That move would make it impossible for the Donald Trump's administration to have a vaccine on the market before the November 3 election, something the president frequently says is on the cards. "Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine's benefit-risk profile," the document said. The two companies that are furthest along in their vaccine trials, Moderna and Pfizer, both began their final stages at the end of July, and both require two separate injections 28 days apart. That would make late November the earliest they could apply to receive emergency use authorizations. The vaccines will have to inoculate half of all patients against Covid-19 and the FDA will need to say at least five cases of people severely ill in the placebo group. "FDA is committed to making the #COVID19 vaccine development process & our scientific evaluation as open & transparent as possible," the agency's head Stephen Hahn wrote on Twitter. The decision to issue the guidance comes amid a reported tug-of-war between the White House and the FDA. According to US media outlets, the White House viewed the two month follow-up period unnecessary and did not want the FDA to implement it. The news was welcomed by health experts who said it showed the agency was acting responsibly in the face of political pressure. ia/ch
schema:headline
  • US agency wants 2 months safety data before approving Covid-19 vaccine
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software